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Abstract
This study aimed to explore the relative contribution of aortic stiffness and volume in treat-
ment-induced change of left ventricular mass in dialysis. Hypertension in Hemodialysis
Patients Treated with Atenolol or Lisinopril trial compared the effect of lisinopril versus aten-
olol in reducing left ventricular mass index; 179 patients with echo measurements of aortic
pulse wave velocity and left ventricular mass at baseline were included. In unadjusted anal-
ysis, overall reductions of 26.24 g/m2 (95% CI: -49.20, -3.29) and 35.67 g/m2 (95% CI:
-63.70, -7.64) in left ventricular mass index were noted from baseline to 6 and 12 months
respectively. Volume control emerged as an important determinant of regression of left ven-
tricular mass index due to the following reasons: (i) additional control for change in ambula-
tory systolic blood pressure mitigated the reduction in left ventricular mass index in the
statistical model above [6-month visit: -18.6 g/m2 (95% CI: -43.7, 6.5); 12-month visit: -22.1
g/m2 (95% CI: -52.2, 8.0)] (ii) regression of left ventricular hypertrophy was primarily due to
reduction in left ventricular chamber and not wall thickness and (iii) adjustment for inferior
vena cava diameter (as a proxy for volume) removed the effect of time on left ventricular
mass index reduction [6-month visit: -6.6 g/m2 (95% CI: (-41.6, 28.4); 12-month visit: 0.6 g/
m2 (95% CI: -39.5, 40.7)]. In contrast, aortic pulse wave velocity was neither a determinant
of baseline left ventricular mass index nor predictor of its reduction. Among dialysis patients,
ambulatory systolic pressure, a proxy for volume expansion, but not aortic stiffness is more
important predictor of reduction in left ventricular mass index. Improving blood pressure
control via adequate volume management appears as an effective strategy to improve left
ventricular hypertrophy in dialysis.
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Introduction
Left ventricular hypertrophy (LVH) is an independent and powerful predictor of cardiovascular
morbidity and mortality both in the general population [1] and among patients with chronic
kidney disease (CKD) [2], including those receiving maintenance hemodialysis therapy [3, 4].
Development of LVH is an early event in the natural course of CKD; LVH progresses over time
in parallel with deterioration of renal function [2]. Thus, in the vast majority of patients who
reach end-stage renal disease (ESRD) and initiate renal replacement therapy LVH is already
established. Among chronic hemodialysis patients it remains largely unclear which factors (left
ventricular cavity dimension or ventricular wall thickness) determine LVH change over time [5].
Among long-term hemodialysis patients, LVH can be either due to hypertrophy of the left
ventricular (LV) wall or dilatation of the LV chamber. Particularly in the setting of volume
expansion, LVH appears to be due to left ventricular chamber dilatation, especially when
patients are unable to reach “dry weight” [5]. In a previous randomized trial, we have shown
that among hypertensive hemodialysis patients, elevated left ventricular mass index (LVMI) is
a marker reflecting volume excess and probing of dry weight during dialysis is associated with
short-term improvement in LVH [6]. This is mainly due to reduction in the LV chamber diam-
eter rather than regression of LV wall hypertrophy.
Another factor proposed to play an important role in promoting the long-term progression
of LVH in hemodialysis patients is impaired mechanical properties of the aorta and large con-
duit arteries due to accelerated arterial stiffening [7, 8]. Arteriosclerosis is considered as one of
the main determinants of increased aortic systolic pressure and pulse pressure, leading to aug-
mented LV work load. Although cross-sectional studies have supported the notion that aortic
stiffness and LVMI maybe interrelated [9, 10], the role of aortic stiffness as predictor of longi-
tudinal change of LVH has never been previously investigated among hemodialysis patients.
The Hypertension in Hemodialysis treated with Atenolol or Lisinopril (HDPAL) study
compared the effect of atenolol versus lisinopril in causing regression of LVH in hemodialysis
patients [11]. In this trial, we directly measured arterial stiffness and volume markers. Accord-
ingly, the aim of the present analysis was to investigate among hypertensive hemodialysis
patients with echocardiographic LVH the relative importance of aortic stiffness and volume as
predictors of treatment-induced decline in LVMI.
Materials and Methods
Study design
The design of the HDPAL randomized trial was previously published [11]. In brief, HDPAL
study compared the effect of 12-month treatment with atenolol versus lisinopril on causing
regression in LVMI in a cohort of 200 ESRD patients receiving standard thrice-weekly hemodi-
alysis therapy for at least 3 months. All patients had hypertension confirmed by 44-hour inter-
dialytic ambulatory blood pressure monitoring (ABPM) and echocardiographic LVH. Patients
were excluded from the study in case of: (i) chronic atrial fibrillation; (ii) body mass index
(BMI)40 kg/m2; (iii) history of missing one or more dialysis treatments within the previous
month; (iv) severe chronic obstructive pulmonary disease; (v) stroke or myocardial infarction
during the previous 6 months; (vi) known contraindication to the randomized drugs.
After a 3-week run-in washout period, eligible patients were randomly assigned in a 1:1
ratio to receive open-label atenolol 25 mg or lisinopril 10 mg both administered 3 times per
week post dialysis. The protocol of the study prespecified dose up-titration of randomized
drugs, administration of other antihypertensive agents on top to the initial regimen, adequate
volume management during dialysis and reducing sodium concentration in the dialysate,
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aiming to lower monthly recorded home blood pressure (BP) below the target of 140/90
mmHg. In case of uncontrolled home BP during the monthly follow-up visits, felodipine or
amlodipine 10mg once daily was added, followed by other antihypertensive medications in the
following order: doxazosin, minoxidil and guanfacine.
Ethics statement
All protocol procedures were conducted in accordance with the Declaration of Helsinki (2000
Amendment) and informed written consent was obtained from each patient prior to study
enrollment. Study protocol was approved by the Institutional Review Board of Indiana Univer-
sity and the Research and Development Committee of the Roudebush VAMedical Center,
Indianapolis, IN, USA.
Study evaluations
Left ventricular mass index. Two-dimensional guided M-mode echocardiograms were
performed by dedicated technicians shortly after dialysis procedure with the use of a digital car-
diac ultrasound device (Cy-press Acuson, Siemens Medical). Echocardiograms were performed
shortly after dialysis, since this period permits better control of hydration status and is associ-
ated with the least intravascular volume. The protocol specified the recording of at least 6 cycles
of 2-dimensional parasternal long- and short-axis left ventricular views with optimal orienta-
tion of the cursor beam to derive additional M-mode recordings [12]. Each patient underwent
6 M-mode measurements of interventricular septal thickness (IVST), LV posterior wall thick-
ness (LVPWT) and left ventricular internal diameter (LVID) all in end-diastole, according to
standard guidelines of the American Society of Echocardiography. Left ventricular mass was
calculated on the basis of a previously validated formula: LV mass (g) = 0.832 x [(IVST+LVID
+LVPWT)3 - (LVID)3]+0.60 [12]. LV mass104 g/m2 in females and116 g/m2 in males
were considered diagnostic of LVH. Echocardiographic evaluations were performed at baseline
and were repeated at 6 and 12 months of follow-up.
Inferior vena cava measurement. Inferior vena cava (IVC) was imaged at the level just
below the diaphragm in the hepatic segment by 2-dismentional guided, M-mode echocardiog-
raphy over 6 cardiac cycles. IVC diameter was measured just before the P wave of the electro-
cardiogram during end expiration and end inspiration, while avoiding Valsalva-like
maneuvers. Collapse index was defined as (maximal diameter on expiration—minimal diame-
ter on deep inspiration)/maximal diameter on expiration X 100. Like LV mass, IVC diameter
was indexed for body surface area. IVC diameter has previously been validated among long-
term hemodialysis patients as a proxy for volume status [13].
Aortic stiffness. Arterial stiffness was assessed by measuring aortic pulse wave velocity
(PWV) through direct visualization of the descending aorta with the use of the above men-
tioned echo-Doppler technique (Acuson Cypress, Seimens Medical). Flow pulse was recorded
by continuous Doppler from the root of the left subclavian artery and just proximal to the
bifurcation of the abdominal aorta with simultaneous electrocardiographic recording [14].
Length of the descending aorta was estimated by measuring the body surface distance from the
suprasternal notch to the recording site of aortic signal (near umbilicus). Time elapsed from
the peak of the R wave to the foot of the systolic impulse was recorded over six beats. The
length of the descending aorta divided by the difference between transit times was calculated to
yield aortic PWV [14].
Ambulatory BP monitoring. ABPM was started immediately after the mid-week dialysis
session and terminated immediately prior to the subsequent dialysis, covering a whole 44 hour
interdialytic period. A cuff of appropriate size was fitted to the non-access arm and ambulatory
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BP recordings were obtained every 20 min during the day-time period (6 AM to 10 PM) and
every 30 min during night-time period (10 PM to 6 AM) with a Spacelab 90207 monitor
(SpaceLabs Medical, Redmond, WA). Hourly means were calculated. These means were there-
after averaged over the entire interdialytic period to provide mean 44-hour ambulatory systolic
BP (SBP) and diastolic BP (DBP). Following the current international recommendation for
ABPM, all patients were given instructions to maintain their usual daily activities during the
recording period [15].
Outcome and predictor variables
LVMI, LVID, IVST, LVPWT at baseline evaluation and their longitudinal change with therapy
were the outcome variables of this analysis. The primary predictor variables were baseline aor-
tic PWV, study visits and their interaction terms as explained in detail below. We further
adjusted the above model for interdialytic ambulatory SBP over 44 hours as a proxy for dry-
weight. Also, we adjusted the model separately for IVC diameter as a proxy for volume status.
Statistical analysis
Continuous variables were expressed as mean ± standard deviations (mean±SDs) and categori-
cal variables as absolutes frequencies and percentages. We divided the study population into
tertiles according to the level of baseline aortic PWV. Comparison of demographic, clinical and
echocardiographic parameters among PWV tertiles was performed with regression analysis for
continuous data and with chi-square test for categorical data.
The primary statistical method used was mixed linear model analysis with fixed and random
effects. Maximal likelihood estimates were used to estimate marginal means. The outcome vari-
able was LVMI. To explore the association of baseline aortic PWV with baseline and treat-
ment-induced reduction in LVMI at 6 and 12 months, we used visits (at 0, 6, and 12 months)
as indicator variables. The independent fixed predictors were visit (as indicator variable), aortic
PWV (as continuous variable), and the interaction of these two terms. Random intercept com-
ponent was the patient and random slopes the visits. LVID, IVST and LVPWT were also ana-
lyzed using separate mixed effects linear models.
The initial models were subsequently adjusted for the following factors: age, gender, race
(black or non-black), smoking, diabetic status, hemoglobin, history of pre-existing cardiovas-
cular disease (defined as myocardial infarction, coronary revascularization, hospitalized
congestive heart failure, peripheral vascular disease and ischemic stroke), treatment arm (aten-
olol or lisinopril) and the interaction term of the randomized drug with follow-up visits.
Subsequently, in order to investigate whether treatment-induced regression in LVH is
explained by BP reduction, we further adjusted the models for the mean interdialytic ambula-
tory SBP at baseline and its change throughout the trial.
Finally, in order to investigate whether treatment-induced regression in LVH is explained by
volume reduction, we further adjusted the models for the post dialysis IVC diameter adjusted for
the body surface area. These measurements were carried out with each measurement of LVMI.
Statistical analysis was performed with Stata version 11.2 (Stata Corp., College Station, TX,
USA). A two-sided p value of<0.05 was considered statistically significant.
Results
Baseline characteristics of study participants
From a total of 200 hypertensive hemodialysis patients with echocardiographic LVH enrolled
in the HDPAL study between August 2005 and September 2013, valid echocardiographic
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measurements of LVMI and aortic PWV were available in 179 subjects. Of the original 200 par-
ticipants, 21 were excluded from the present analysis due to the following reasons: 17 subjects
did not have their PWV assessed and 4 subjects had technically inaccurate PWVmeasurement
at study enrollment. Among 179 HDPAL participants included in this analysis, 114 patients
were assessed at the 6-month and 83 patients were assessed at the 12-month follow-up visit.
Baseline characteristics of study participants according to the tertile of baseline aortic PWV
are presented in Table 1. The study included 119 male and 60 female hemodialysis patients
with a mean age of 52.1±12.4 years who were predominantly black in race (87.2%). Patients
lying within the highest PWV tertile were older in age and had a greater prevalence of diabetes
mellitus. However, gender, race, history of previous cardiovascular disease, smoking, type of
dialysis access and other clinical and laboratory evaluations were evenly distributed among
PWV subgroups.
Background antihypertensive treatment of study participants is depicted in Table 2. Almost
96.7% of study participants were previously treated for hypertension, receiving a mean number
of 2.7±1.3 drugs daily. Blockers of the renin-angiotensin-aldosterone system and beta-blockers
were the most commonly prescribed antihypertensive medications. No difference in the num-
ber and nature of BP-lowering drugs was evident among PWV tertiles, with the exception of
non-dihydropyridine and dihydropyridine calcium-channel-blockers that were more com-
monly prescribed in the highest PWV terile.
Table 1. Baseline characteristics of study participants according to the tertile of baseline aortic pulse wave velocity.
Clinical characteristic PWV tertile Low PWV tertile Medium PWV tertile High Overall P Value
N 60 60 59 179
Pulse wave velocity (m/s) 5 ± 0.8 7.2 ± 0.6 10.6 ± 2.2 7.6 ± 2.7 <0.001
Age (y) 47.7 ± 10.9 51.1 ± 12 57.7 ± 12.4 52.1 ± 12.4 <0.001
Male sex n(%) 38 (63.3%) 41 (68.3%) 40 (67.8%) 119 (66.5%) 0.82
Blacks n(%) 54 (90%) 53 (88.3%) 49 (83.1%) 156 (87.2%) 0.5
Hispanic n(%) 0 (0%) 1 (1.7%) 0 (0%) 1 (0.6%) 0.37
Atenolol n(%) 28 (46.7%) 33 (55%) 28 (47.5%) 89 (49.7%) 0.6
Diabetes mellitus n(%) 14 (23.3%) 26 (43.3%) 35 (59.3%) 75 (41.9%) <0.001
Anuric n(%) 37 (60.7%) 40 (65.6%) 42 (73.7%) 119 (66.5%) 0.14
Hospitalized heart failure n(%) 15 (25%) 21 (35%) 16 (27.1%) 52 (29.1%) 0.45
Coronary artery disease n(%) 13 (21.7%) 18 (30%) 13 (22%) 44 (24.6%) 0.49
Coronary revascularization n(%) 1 (1.7%) 8 (13.3%) 4 (6.8%) 13 (7.3%) 0.05
Cerebrovascular disease n(%) 6 (10%) 13 (21.7%) 10 (16.9%) 29 (16.2%) 0.22
Peripheral vascular disease n(%) 3 (5%) 6 (10%) 8 (13.6%) 17 (9.5%) 0.28
Smoking n(%) 33 (55%) 26 (43.3%) 21 (35.6%) 80 (44.7%) 0.1
Height (in) 67.9 ± 3.5 68 ± 4.1 68 ± 4.1 68 ± 3.9 0.99
Weight (kg) 82.3 ± 28.1 83.9 ± 23.4 80.8 ± 18 82.3 ± 23.5 0.77
Body mass index (kg/m2) 27.7 ± 9.4 28.1 ± 7.2 27.2 ± 6.9 27.7 ± 7.9 0.85
Access type 0.29
Fistula 34 (56.7%) 32 (53.3%) 39 (66.1%) 105 (58.7%) 0.34
Graft 12 (20%) 8 (13.3%) 5 (8.5%) 25 (14%) 0.19
Catheter 14 (23.3%) 20 (33.3%) 15 (25.4%) 49 (27.4%) 0.43
Delivered dialysis duration (min) 220.4 ± 40.5 222.5 ± 36.8 224.4 ± 28.5 222.4 ± 35.5 0.83
Albumin (g/dL) 3.7 ± 0.5 3.6 ± 0.4 3.5 ± 0.4 3.6 ± 0.5 0.19
Hemoglobin (g/dL) 11.6 ± 1.2 11.3 ± 1.5 11.1 ± 1.3 11.3 ± 1.3 0.12
doi:10.1371/journal.pone.0135457.t001
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Interdialytic ambulatory BP and indices of left ventricular structure at
baseline
As shown in Table 3, higher PWV was associated with elevated mean 44-hour interdialytic
ambulatory SBP levels at baseline, whereas mean 44-hour ambulatory DBP and heart rate were
no different between PWV tertiles. Baseline levels of LVMI did not significantly differ among
PWV subgroups; similarly, increasing baseline aortic PWV was not associated with rise in
LVID, IVST and LVPWT.
Predictors of LVH at baseline and its longitudinal response to treatment
LVMI. Table 4 and Fig 1 show the predictors of LVMI change over time. In unadjusted
analysis, significant effect of visits indicates that LVMI was significantly reduced from baseline
to 6 months (β -26.2 g/m2; p = 0.03) and from baseline to 12 months (β -35.7 g/m2 p = 0.01).
The interaction term of PWV x visit was not significant indicating no association of PWV with
regression of LVMI. The aortic PWV was neither associated with LVMI at baseline (β -1.6 g/m2
Table 2. Number and class of antihypertensive medications according to the tertile of aortic pulse wave velocity.
Parameter PWV tertile Low PWV tertile Medium PWV tertile High Overall P Value
N 60 60 59 179
Antihypertensive drugs (n) 2.6 ± 1.3 2.7 ± 1.4 2.9 ± 1.2 2.7 ± 1.3 0.42
No antihypertensive drug n(%) 2 (3.3%) 3 (5%) 1 (1.7%) 6 (3.4%) 0.61
ACE inhibitors n(%) 42 (70%) 35 (58.3%) 37 (62.7%) 114 (63.7%) 0.41
ARBs n(%) 5 (8.3%) 6 (10%) 8 (13.6%) 19 (10.6%) 0.64
Beta-blockers n(%) 47 (78.3%) 44 (73.3%) 46 (78%) 137 (76.5%) 0.77
Alpha-blockers n(%) 8 (13.3%) 5 (8.3%) 6 (10.2%) 19 (10.6%) 0.67
Centrally acting agents n(%) 17 (28.3%) 23 (38.3%) 20 (33.9%) 60 (33.5%) 0.51
Non dihydropydine CCBs n(%) 0 (0%) 7 (11.7%) 1 (1.7%) 8 (4.5%) <0.01
Dihydropydine CCBs n(%) 24 (40%) 27 (45%) 38 (64.4%) 89 (49.7%) 0.02
Vasodilators n(%) 15 (25%) 14 (23.3%) 15 (25.4%) 44 (24.6%) 0.96
Loop diuretics n(%) 0 (0%) 0 (0%) 2 (3.4%) 2 (1.1%) 0.13
Abbreviations: PWV = pulse wave velocity; ACE = angiotensin converting enzyme; ARBs = angiotensin receptor blockers; CCBs = calcium channel
blockers
doi:10.1371/journal.pone.0135457.t002
Table 3. Interdialytic ambulatory BP and indices of left ventricular structure at baseline.
Parameter PWV Tertile Low PWV Tertile Medium PWV Tertile High Overall P value
N 60 60 59 179
44-hour ambulatory SBP (mmHg) 148.1 ± 13.4 151.4 ± 13.2 155.8 ± 16.1 151.7 ± 14.5 0.01
44-hour ambulatory DBP (mmHg) 88.8 ± 10.4 88.3 ± 12.7 86.1 ± 12.3 87.8 ± 11.8 0.41
44-hour heart rate (bpm) 79.2 ± 11 82.9 ± 11.7 79.7 ± 13.2 80.6 ± 12 0.19
LVMI (g/m2) 178.4 ± 53.6 176.6 ± 51.3 167.7 ± 38.8 174.4 ± 48.5 0.45
IVST (cm) 1.54 ± 0.33 1.58 ± 0.3 1.52 ± 0.25 1.55 ± 0.29 0.54
LVPWT (cm) 1.48 ± 0.3 1.55 ± 0.26 1.47 ± 0.21 1.5 ± 0.26 0.23
LVID (cm) 5.06 ± 0.64 4.95 ± 0.77 4.96 ± 0.63 4.99 ± 0.68 0.64
Abbreviations: PWV = pulse wave velocity; SBP = systolic blood pressure; DBP = diastolic blood pressure; LVMI = left ventricular mass index;
IVST = interventricular septal thickness; LVPWT = left ventricular posterior wall thickness; LVID = left ventricular internal diameter
doi:10.1371/journal.pone.0135457.t003
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p = 0.23) nor with LVMI decline during follow-up (overall p value for PWVvisit interaction
term = 0.16) (Table 4).
After adjustment for age, gender, race, smoking, diabetic status, history of previous cardio-
vascular disease, hemoglobin levels, treatment arm and drug effect over time, decrease in
LVMI from baseline to 6 months (β -26.0, p = 0.03) and baseline to 12 months (β -34.8, p =
0.02) remained statistically significant.
Additional adjustment (of Model 2) for the change in ambulatory SBP over time (Model 3
in Table 4) mitigated the treatment-induced reduction in LVMI (β -18.6, p = 0.15 at 6-months
and β -22.1, p = 0.15 at 12-months) (see also Fig 1). Again, aortic PWV was neither an indepen-
dent determinant of LVMI at baseline (p = 0.09) nor a predictor of the change in LVMI during
follow-up (overall p value for the PWVvisit interaction term = 0.19).
Table 4. Progressively adjustedmodels of change from baseline in left ventricular mass index.
Model Mean (95% CI) P value Overall P value
Model 1: Unadjusted
6-month visit -26.2(-49.2–-3.3) 0.03 0.02
12-month visit -35.7 (-63.7–-7.6) 0.01
6-month visit*PWV 2.7 (-0.2–5.5) 0.07 0.16
12-month visit*PWV 2.1 (-1.5–5.7) 0.26
PWV at baseline visit -1.6 (-4.2–1.0) 0.23
Constant 186.5 (165.4–207.5) <0.001
Model 2: Adjusted for age, sex, race, smoking, diabetes, CVD, treatment arm, drug effect over time
6-month visit -26.0 (-50.2–-1.9) 0.03 0.02
12-month visit -34.8 (-63.4–-6.1) 0.02
6-month visit*PWV 2.4 (-0.4–5.3) 0.09 0.22
12-month visit*PWV 1.9 (-1.7–5.5) 0.3
PWV at baseline visit -2.0 (-4.7–0.7) 0.15
Constant 254.4 (186.6–322.2) <0.001
Model 3: adjusted for factors in model 2 +ambulatory SBP at baseline and over time
6-month visit -18.6 (-43.7–6.5) 0.15 0.22
12-month visit -22.1 (-52.2–8.0) 0.15
6-month visit*PWV 2.7 (-0.2–5.7) 0.07 0.19
12-month visit*PWV 1.5 (-2.2–5.2) 0.43
PWV at baseline visit -2.3 (-5.1–0.4) 0.09
Constant 203.5 (105.1–301.9) <0.001
Model 4: adjusted for factors in model 2 +IVC diameter at baseline and over time
6-month visit -6.6 (-41.6–28.4) 0.71 0.91
12-month visit 0.6 (-39.5–40.7) 0.98
6-month visit*PWV 2.0 (-0.9–4.8) 0.18 0.41
12-month visit*PWV 0.9 (-2.8–4.6) 0.64
PWV at baseline visit -1.7 (-4.4–1.0) 0.23
Constant 224.9 (152.9–297.0) <0.001
Abbreviations: CI = conﬁdence intervals of the mean; PWV = pulse wave velocity; CVD = cardiovascular
disease; SBP = systolic blood pressure; IVC = inferior vena cava diameter (cm/m2) in expiration. Change
from baseline in LVMI is expressed in g/m2. The PWV*visit interaction term is expressed as g/m2 change in
LVMI per each 1 m/sec increase in PWV.
doi:10.1371/journal.pone.0135457.t004
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To further explore the provenance of LVMI reduction, additional adjustment (of Model 2)
for the change in IVC diameter over time (Model 4 in Table 4) essentially abolished the treat-
ment-induced reduction in LVMI.
Cavitary and muscular components of left ventricle. As shown in Fig 1, in unadjusted
analysis, significant treatment-induced reductions from baseline to 6 and 12 months were evi-
dent for LVID (β -0.44 for the 6-month visit and β -0.44 for the 12-month visit, p = 0.03 for
overall visit effect). In contrast, treatment with either lisinopril- or atenolol-based regimen was
not associated with improvement in the LV muscular compartment, as both IVST and
LVPWT remained unchanged during the 12-month follow-up period (Fig 1).
After adjustment for several cardiovascular risk factors (age, gender, black race, smoking
status, presence of diabetes, history of pre-existing cardiovascular disease, hemoglobin,
Fig 1. Treatment-induced change in left ventricular mass index and in cavitary andmuscular components of left ventricle. The Y-axis shows the
change from baseline (CFB) to 6 and 12 months of treatment in a) left ventricular mass index (LVMI); b) left ventricular internal diameter (LVID); c)
interventricular septal thickness (IVST); and d) left ventricular posterior wall thickness (LVPWT). The x-axis shows the months of treatment. Shades of the
bars represent progressive adjustments to the models with the darker bar representing the full-adjusted models. The error bars represent 95% confidence
intervals of the means derived frommixed linear model analysis. In unadjusted analysis, LVMI and LVID were significantly reduced from baseline to 6 and 12
months in contrast to IVST and LVPWT that remained unchanged. After adjustment for age, gender, race, smoking, diabetic status, history of previous
cardiovascular disease, hemoglobin levels, treatment arm and drug effect over time, CFB to 6 and 12 months in LVMI and LVID remained significant;
however, additional adjustment for the CFB in 44-hour ambulatory systolic blood pressure or IVC diameter mitigated the reduction in LVMI and LVID. IVST
and LVPWT remained constant during follow-up in both adjusted models.
doi:10.1371/journal.pone.0135457.g001
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randomized drug and drug effect over time), change in LVID from baseline to 6 months (β
-0.44; 95% CI: -0.81, -0.07, p = 0.02) as well as from baseline to 12 months (β -0.49; 95% CI:
-0.97, -0.01, p = 0.047) remained significant (overall visit effect p = 0.03). Additional adjust-
ment for ambulatory SBP at baseline and its change throughout the trial removed the effect of
treatment on the change in LVID at 6 months (β -0.35; 95% CI: -0.73, 0.04, p = 0.08) and 12
months of follow-up (β -0.34; 95% CI: -0.85, 0.17, p = 0.19). Similarly, adjustment for IVC
diameter at baseline and its change over time removed the effect of treatment-induced change
in LVID at any time point. The overall visit effect became non-significant (p = 0.17). As shown
in Fig 1, both IVST and LVPWT remained unchanged over time in adjusted analyses.
Discussion
Major findings of the present study were that among hypertensive hemodialysis patients with
echocardiographic LVH: (i) increasing aortic PWV was not determinant of the LVMI at base-
line and was unable to predict the treatment-induced reduction in LVMI over 12 months of
follow-up; (ii) treatment-induced decline in LVMI was independent from age, gender, race,
several other cardiovascular risk factors, treatment arm and drug effect over time; (iii) treat-
ment-induced decline in LVMI was mitigated by reduction in ambulatory SBP which supports
the hypothesis that volume is in the causal pathway of decline in LVMI; (iv) treatment-induced
decline in LVMI was mitigated by reduction in IVC diameter which directly supports the
notion that volume is in the causal pathway of decline in LVMI; (v) lowering of LVMI during
the 12-month follow-up was mediated predominantly through reduction in the cavitary com-
ponent of left ventricle instead of improvement in LV wall thickness. Taken together, these
observations support the notion that volume (rather than arterial stiffness) is major mediator
of decline in LVMI.
The finding of the present study that aortic PWV was neither determinant of baseline
LVMI nor predictor of the treatment-induced decline in LVMI over time is in line with the
results of previous studies conducted in the general hypertensive population, showing that
impaired mechanical properties of large arteries did not influence the efficacy of antihyperten-
sive treatment in causing regression of LVH [16, 17]. In an observational analysis of 61 patients
with essential hypertension, Hashimoto et al. [16] showed that neither aortic PWV nor transit
time of pulse wave were predictors of reduction in LVMI after 12 months of antihypertensive
treatment. This is strongly supported by the results of a post-hoc analysis of the Losartan Inter-
vention For Endpoint reduction in hypertension (LIFE) echo sub-study [17], in which reduced
ratio of pulse pressure to stroke volume (PP/SVi), an index reflective of systemic arterial com-
pliance, was associated with greater BP reduction, but was unable to predict the decline in
LVMI over 5-year-long treatment with either losartan or atenolol in 960 patients with essential
hypertension and echocardiographic LVH.
The most important finding of the present work was that LVMI lowering in the HDPAL
trial was strongly associated with the change in 44-hour ambulatory SBP (a proxy of achieve-
ment of dry weight) and with change in IVC diameter (a proxy for achievement of volume con-
trol) during follow-up. Indeed, additional adjustment of the models for the longitudinal
reduction in interdialytic BP load or IVC diameter removed the significant effect of visits on
LVMI and LVID, indicating that LVH regression was largely volume-mediated (Fig 1). In addi-
tion, among cavitary and muscular compartments of left ventricle, the present study showed
that treatment-induced regression of LVMI was predominantly due to reduction in LV cham-
ber dilatation rather than improvement in LV wall thickness. It is likely that such an effect (i.e.,
decrease in LVID but not in IVST and LVPWT) may be due to better achievement of dry
weight over time [18, 19]. These findings are in sharp contrast to those reported in populations
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without ESRD such as in the LIFE study which used non-volume reduction strategies to reduce
BP [20]. In the LIFE study, treatment-induced reduction in LVMI with either atenolol or losar-
tan was predominantly due to reductions in thickness of the ventricular wall (IVST and
LVPWT). In fact, with either drug, the LVID increased [20]. Diuretic use was no different in
the two treatment groups. In the Trial of Mild Hypertension Study, treatment-induced reduc-
tion in LVMI over one year was reported for 5 antihypertensive agents: amlodipine, acebutalol,
doxazosin, enalapril and chlorthalidone [21]. Compared to others, greatest reduction in LVID
was seen with chlorthalidone treatment. Together these findings suggest that among hyperten-
sive hemodialysis patients with echocardiographic LVH, strict volume control may be the pre-
dominant mechanism that evokes a reduction in LVMI. This study was conducted in a subset
of dialysis patients treated with specific antihypertensive medications within a randomized
controlled trial. However, volume-mediated improvement in LVMI may be relevant for the
whole hemodialysis population, since probing of dry-weight represents the main non-pharma-
ceutical therapeutic approach to achieve adequate BP control in these patients [22]. These find-
ings are also consistent with non-ESRD populations where a volume reduction strategy such as
with diuretics also evokes reduction in LVMI.
In the Dry Weight Reduction in Hypertensive Hemodialysis Patients (DRIP) trial, we have
previously shown that among 150 hypertensive hemodialysis patients, probing of dry weight
over a 24-dialysis treatment period culminated in a significantly greater reduction of 10.9 g/m2
in LVMI as compared to the standard ultrafiltration [6]. The present study expands our previ-
ous observations, showing that over a longer 12-month treatment period reduced exposure of
myocardium to the interdialytic volume and pressure overload was the major pathway of LVH
regression. This notion is also supported by another recent study, in which volume manage-
ment through dietary sodium restriction and intensified ultrafiltration during dialysis was
associated with reduced LVMI and improved LV function at both systole and diastole [23]. In
a recent pilot study, strict volume control through bioelectrical impendence-guided manage-
ment of dry-weight was associated with greater improvement in LVMI in comparison with the
clinically-guided adjudication of volume status [24]. In addition, the Frequent Hemodialysis
Network (FHN) trial showed that short daily hemodialysis, a treatment intervention that
enhances volume withdrawal over a longer dialysis time and probes achievement of dry weight,
caused a greater regression in LVMI relative to conventional thrice-weekly hemodialysis over
12 months of follow-up [25].
This study has several strengths and limitations. Important strength of this work was that
the protocol prespecified echocardiographic evaluation of LV structure at repeated time-points
during follow-up to adequately capture treatment-induced changes in LVMI and related
parameters in the context of a randomized controlled trial. To mitigate the effect of volume on
cavity dimensions, we fixed the time of echocardiography to immediately post dialysis.
Strength of this study was also the use of the most reliable method of 44-hour ABPM in an
attempt to properly evaluate the true BP load imposed to the left ventricle during the entire
interdialytic period. Of note, peridialytic BP recordings exhibit extensive variability, poor
reproducibility and provide inaccurate estimates of 44-hour interdialytic ambulatory BP [22,
26]. Furthermore, we used a direct and validated measure of volume—echocardigraphically
measured IVC diameter. However, this study has also some limitations. This study did not
include determination of central aortic pressures and wave reflection indices, which are also
important components arterial cushioning function [7]; thus, whether amplitude and timing of
wave reflections from peripheral vascular beds are determinants of LVMI at baseline or predic-
tors of its longitudinal change cannot be established in the present study. Further, echo-derived
measurements of aortic PWV were not previously validated against invasive (gold-standard)
measurements in dialysis patients; however, none of the currently available techniques for
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non-invasive aortic PWV assessment was particularly tested against intra-aortic measurements
in this specific population. Last, his study is an analysis of a single-center trial and a large num-
ber of participants were African-Americans; whether the results of this study are generalizable
in other patient populations with different racial and ethnic characteristics remains uncertain.
Conclusion
Among hypertensive hemodialysis patients with echocardiographic LVH, volume-mediated
reduction in interdialytic ambulatory BP but not severity of aortic stiffness is a more important
predictor of treatment-induced reduction in LVMI. To the extent this cause-and-effect associa-
tion is true, strict volume control and probing of dry weight appear as effective therapeutic
approaches to improve LVH and potentially reduce risk of cardiovascular morbidity and mor-
tality in hemodialysis patients.
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